GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year on a reported basis and 10% at a constant exchange rate (CER) due to increased operating expenses during the quarter.
GSK (NYSE:GSK) Shares Gap Up on Earnings Beat
GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06. GSK shares last traded at $37.
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
GSK lifts 2031 sales target after better-than-expected Q4
GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccines.
GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance in 2024.
FiercePharma2d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
FierceBiotech26d
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.
pharmaphorum5d
GSK confirms plan to buy cancer firm IDRx for $1bn
In a statement, GSK chief commercial officer Luke Miels said that the drug "complements [the company's] growing portfolio in gastrointestinal cancers," which also includes anti-PD-1 antibody ...
The Business Journals25d
GSK shells out $1B upfront for Plymouth cancer biotech
chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...
GSK targets £40bn in sales as HIV and cancer drugs offset vaccine weakness
The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of ...
Yahoo Finance26d
GSK Enters Agreement to Acquire IDRx, Inc.
Luke Miels, Chief Commercial Officer, GSK, said: "IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...